The board of directors of JACOBIO PHARMACEUTICALS Group CO., LTD. announced that the Group has received the Investigational New Drug approval for LIF mAb JAB-BX300 from the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) on April 4, 2023. The Group plans to initiate a Phase I/IIa clinical trial for JAB-BX300 on advanced solid tumors in China. LIF is an important biomarker in pancreatic ductal adenocarcinoma (PDAC).

Relevant research show that, LIF plays a crucial role in KRAS-driven cancer models and the blockade of LIF by antibodies represents an attractive approach to improve therapeutic outcomes. JAB-BX300 shows significant anti-tumor activity in humanized pancreatic PDX mouse models. LIF expression is induced specifically by oncogenic KRAS and studies show that LIF is an attractive target for the treatment of KRAS-driven tumors.

The Group has several programs in KRAS signaling pathway, including SHP2 inhibitor (JAB-3312 & JAB-3068), Glesirasib (KRAS G12C inhibitor JAB-21822) and KRAS multi inhibitor (JAB-23400), which have potential to combo with LIF mAb. Jacobio is committed to developing global first-in-class drugs, and key programs are targeting among the top three worldwide. Currently there is only one LIF mAb program in the Phase II clinical stage in respective drug class globally.